DTx-1252

DTx-1252 is a potential first-in-class small interfering RNA (siRNA) therapeutic developed using the FALCON (Fatty Acid Ligand Conjugated OligoNucleotides) platform. It is designed to treat Charcot-Marie-Tooth Disease Type 1A (CMT1A), a progressive, inherited neuromuscular disorder. The drug works by inhibiting the expression of peripheral myelin protein 22 (PMP22), which is overexpressed in CMT1A and leads to defective myelination of peripheral nerves. Preclinical studies have shown that DTx-1252 can induce remyelination, improve nerve function, and restore muscle strength and coordination in animal models. The therapy has received Orphan Drug Designation from the FDA for CMT1A[1][3][7][9].